{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T03:11:41Z","timestamp":1789269101138,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Metastatic triple-negative breast cancer (BC; mTNBC) is one of the most aggressive cancers, difficult to treat due to the absence of hormone target receptors. Sacituzumab govitecan (SG) is a new therapeutic approach that exploits the combination of an antibody directed against the Trop-2 antigen expressed in solid epithelial tumors and the active metabolite SN-38, to precisely target cancer cells. The development of consensus recommendations requires synthesizing expert opinions, especially when direct evidence is limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study aimed to create a Delphi process to gather the perspectives of a panel of BC and supportive specialists on the use of SG in clinical practice. A scientific board discussed and defined a series of statements that were submitted to the panel through 2 rounds of voting. The process was designed to collect expert opinions to achieve consensus on key points regarding the safety, dosing regimens, and patient management for SG. Each round of the survey included targeted questions informed by current literature. Predefined criteria for consensus were set at \u226575% agreement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In October 2024, 29 experts\u2019 opinions were collected by voting on 40 statements and reaching a 67% agreement. The reduction of the initial SG dose and the management of prophylaxis for patients with the UGT1A1 *28\/*28 genotype were the most discussed topics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results provide a foundational framework for clinical decision-making, and highlight the importance of collaborative expert synthesis in forming practice guidelines. Future studies should focus on prospective SG trials to address the identified areas of uncertainty.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf088","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T13:24:32Z","timestamp":1747229072000},"source":"Crossref","is-referenced-by-count":4,"title":["Delphi consensus on the management of adverse events in patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan"],"prefix":"10.1093","volume":"30","author":[{"given":"Anna Amela","family":"Valsecchi","sequence":"first","affiliation":[{"name":"Department of Oncology, University of Turin, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Ospedale Molinette , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Pisegna","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome , Rome ,","place":["Italy"]},{"name":"Medical Oncology Unit, Sant\u2019Andrea Hospital of Rome , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Antonuzzo","sequence":"additional","affiliation":[{"name":"Internistic and Geriatric Supportive Care, Fondazione IRCCS - National Cancer Institute , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Arpino","sequence":"additional","affiliation":[{"name":"Oncology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6790-6267","authenticated-orcid":false,"given":"Giampaolo","family":"Bianchini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Ospedale San Raffaele , Milano ,","place":["Italy"]},{"name":"School of Medicine, Vita-Salute San Raffaele University , Milano ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Biganzoli","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hospital of Prato, Azienda USL Toscana Centro ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe Ferdinando","family":"Colloca","sequence":"additional","affiliation":[{"name":"Department of Imaging Diagnostic, Oncologic Radiotherapy and Haematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9064-0113","authenticated-orcid":false,"given":"Carmen","family":"Criscitiello","sequence":"additional","affiliation":[{"name":"Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS , Milan ,","place":["Italy"]},{"name":"Department of Oncology and Hematology-Oncology (DIPO), University of Milan , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4414-8934","authenticated-orcid":false,"given":"Romano","family":"Danesi","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, University of Milano \u201cLa Statale,\u201d Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fabi","sequence":"additional","affiliation":[{"name":"Precision Medicine Unit in Senology, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4592-8868","authenticated-orcid":false,"given":"Raffaele","family":"Giusti","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Sant\u2019Andrea Hospital , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loredana","family":"Pau","sequence":"additional","affiliation":[{"name":"Europa Donna Italia , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-3785","authenticated-orcid":false,"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Ospedale Molinette , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[{"name":"Medical-Surgical Sciences and Biotechnology, La Sapienza University of Rome , Rome ,","place":["Italy"]},{"name":"Medical Oncology A, Policlinico Umberto 1 , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"2025052712004139100_CIT0001","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.3390\/cancers16193250","article-title":"Present and future of immunotherapy for triple-negative breast cancer","volume":"16","author":"Sriramulu","year":"2024","journal-title":"Cancers."},{"key":"2025052712004139100_CIT0002","doi-asserted-by":"publisher","first-page":"103821","DOI":"10.1016\/j.breast.2024.103821","article-title":"Chemotherapy in older patients with early breast cancer","volume":"78","author":"Schmidt","year":"2024","journal-title":"Breast."},{"key":"2025052712004139100_CIT0003","doi-asserted-by":"publisher","first-page":"103713","DOI":"10.1016\/j.esmoop.2024.103713","article-title":"Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer","volume":"9","author":"Quintana","year":"2024","journal-title":"ESMO Open."},{"key":"2025052712004139100_CIT0004","doi-asserted-by":"publisher","first-page":"100204","DOI":"10.1016\/j.esmoop.2021.100204","article-title":"Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape","volume":"6","author":"Adams","year":"2021","journal-title":"ESMO Open."},{"key":"2025052712004139100_CIT0005","doi-asserted-by":"publisher","first-page":"100497","DOI":"10.1016\/j.esmoop.2022.100497","article-title":"The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer","volume":"7","author":"Michaleas","year":"2022","journal-title":"ESMO Open."},{"key":"2025052712004139100_CIT0006","doi-asserted-by":"publisher","first-page":"103830","DOI":"10.1016\/j.breast.2024.103830","article-title":"Unveiling the future of breast cancer therapy: cutting-edge antibody-drug conjugate strategies and clinical outcomes","volume":"78","author":"Sun","year":"2024","journal-title":"Breast."},{"key":"2025052712004139100_CIT0007","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.3390\/cancers16213622","article-title":"Sacituzumab govitecan in triple negative breast cancer: a systematic review of clinical trials","volume":"16","author":"P\u00e9rez-Bermejo","year":"2024","journal-title":"Cancers."},{"key":"2025052712004139100_CIT0008","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann Oncol."},{"key":"2025052712004139100_CIT0009","doi-asserted-by":"publisher","first-page":"S200","DOI":"10.1016\/j.annonc.2022.03.187","article-title":"168P Sacituzumab govitecan (SG) efficacy in patients with metastatic triple-negative breast cancer (mTNBC) by HER2 immunohistochemistry (IHC) status: findings from the phase III ASCENT study","volume":"33","author":"Hurvitz","year":"2022","journal-title":"Ann Oncol."},{"key":"2025052712004139100_CIT0010","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"npj Breast Cancer."},{"key":"2025052712004139100_CIT0011","doi-asserted-by":"publisher","first-page":"LBA1001","DOI":"10.1200\/jco.2022.40.17_suppl.lba1001","article-title":"Primary results from TROPiCS-02: a randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician\u2019s choice (TPC) in patients (Pts) with hormone receptor\u2013positive\/HER2-negative (HR+\/HER2-) advanced breast cancer","volume":"40","author":"Rugo","year":"2022","journal-title":"J Clin Oncol."},{"key":"2025052712004139100_CIT0012","doi-asserted-by":"publisher","first-page":"5694","DOI":"10.3390\/curroncol31090422","article-title":"Canadian Expert Recommendations on Safety Overview and Toxicity management strategies for sacituzumab govitecan based on use in metastatic triple-negative breast cancer","volume":"31","author":"Manna","year":"2024","journal-title":"Curr Oncol."},{"key":"2025052712004139100_CIT0013","doi-asserted-by":"publisher","first-page":"S381","DOI":"10.1016\/j.annonc.2024.08.338","article-title":"390P SARELIFE: an Italian, multicentric real-world study of sacituzumab govitecan (SG) in pretreated metastatic triple-negative breast cancer (mTNBC)","volume":"35","author":"Cona","year":"2024","journal-title":"Ann Oncol."},{"key":"2025052712004139100_CIT0014","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1200\/jco.2024.42.16_suppl.1101","article-title":"Prevention of sacituzumab govitecan (SG)-related neutropenia and diarrhea in patients (pts) with triple-negative or HR+\/HER2- advanced breast cancer (ABC; PRIMED): a phase 2 trial","volume":"42","author":"P\u00e9rez Garc\u00eda","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025052712004139100_CIT0015","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients","volume":"18","author":"Klastersky","year":"2000","journal-title":"J Clin Oncol."},{"key":"2025052712004139100_CIT0016","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00520-023-08222-3","article-title":"2023 updated MASCC\/ESMO Consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents","volume":"32","author":"Scott\u00e9","year":"2024","journal-title":"Support Care Cancer."},{"key":"2025052712004139100_CIT0017","doi-asserted-by":"publisher","first-page":"17588359231200454","DOI":"10.1177\/17588359231200454","article-title":"Safety and effectiveness of sacituzumab govitecan in patients with metastatic triple-negative breast cancer in real-world settings: first observations from an interdisciplinary breast cancer centre in Germany","volume":"15","author":"Reinisch","year":"2023","journal-title":"Ther Adv Med Oncol."},{"key":"2025052712004139100_CIT0018","doi-asserted-by":"crossref","article-title":"Clinical outcomes by age subgroups in the phase 3 TROPiCS-02 study of sacituzumab govitecan vs treatment of physician\u2019s choice in HR+\/HER2\u2013 metastatic breast cancer","author":"Bardia","DOI":"10.1158\/1538-7445.SABCS23-PO5-21-09"},{"key":"2025052712004139100_CIT0019","doi-asserted-by":"publisher","first-page":"104265","DOI":"10.1016\/j.critrevonc.2024.104265","article-title":"UGT1A1 Testing in Breast Cancer: should it become routine practice in patients treated with antibody-drug conjugates","volume":"196","author":"Ibrahim","year":"2024","journal-title":"Crit Rev Oncol Hematol."},{"key":"2025052712004139100_CIT0020","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med."},{"key":"2025052712004139100_CIT0021","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1200\/JCO.23.01409","article-title":"Final results from the randomized phase III ASCENT clinical trial in metastatic triple-negative breast cancer and association of outcomes by human epidermal growth factor receptor 2 and trophoblast cell surface antigen 2 expression","volume":"42","author":"Bardia","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025052712004139100_CIT0022","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1002\/cpt.3495","article-title":"Exposure\u2013response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic triple-negative breast cancer","volume":"117","author":"Sathe","year":"2024","journal-title":"Clin Pharmacol Ther."},{"key":"2025052712004139100_CIT0023","doi-asserted-by":"publisher","first-page":"1276976","DOI":"10.3389\/fonc.2023.1276976","article-title":"Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system","volume":"13","author":"Gui","year":"2023","journal-title":"Front Oncol."},{"key":"2025052712004139100_CIT0024","doi-asserted-by":"publisher","first-page":"1362641","DOI":"10.3389\/fonc.2024.1362641","article-title":"Sacituzumab Govitecan for the treatment of advanced triple negative breast cancer patients: a multi-center real-world analysis","volume":"14","author":"Caputo","year":"2024","journal-title":"Front Oncol."},{"key":"2025052712004139100_CIT0025","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s44276-024-00106-1","article-title":"Efficacy and safety of sacituzumab govitecan Trop-2-targeted antibody-drug conjugate in solid tumors and UGT1A1*28 polymorphism: a systematic review and meta-analysis","volume":"2","author":"Sultana","year":"2024","journal-title":"BJC Rep."},{"key":"2025052712004139100_CIT0026","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3390\/cancers13071566","article-title":"UGT1A1 guided cancer therapy: review of the evidence and considerations for clinical implementation","volume":"13","author":"Nelson","year":"2021","journal-title":"Cancers."},{"key":"2025052712004139100_CIT0027","doi-asserted-by":"publisher","first-page":"1389968","DOI":"10.3389\/fphar.2024.1389968","article-title":"Genetic variation in UGT1A1 is not associated with altered liver biochemical parameters in healthy volunteers participating in bioequivalence trials","volume":"15","author":"Gonz\u00e1lez-Iglesias","year":"2024","journal-title":"Front Pharmacol."},{"key":"2025052712004139100_CIT0028","doi-asserted-by":"publisher","first-page":"103211","DOI":"10.1016\/j.esmoop.2024.103211","article-title":"189P The impact of high body mass index (BMI) on the safety and efficacy of sacituzumab govitecan (SG) in patients (pts) with metastatic triple-negative breast cancer (mTNBC) from ASCENT","volume":"9","author":"Estevez","year":"2024","journal-title":"ESMO Open."}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf088\/63179018\/oyaf088.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/5\/oyaf088\/63179018\/oyaf088.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T16:00:50Z","timestamp":1748361650000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf088\/8131373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf088","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"oyaf088"}}